Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
收藏官方服务：
资源简介：
Randomized, double-blind, placebo-controlled clinical trial of Ad26.COV2.S on 25 participants. Participants were randomized to receive single-shot and 2-shot vaccine regimens with either 5 X 1010 or 1 X 1011 viral particles of Ad26.COV2.S or placebo in healthy adults 18 to 55 years of age.
提供机构：
ImmPort创建时间：
2022-08-26
